NovaBridge Biosciences (NBP) Equity Average (2018 - 2025)

NovaBridge Biosciences (NBP) has 7 years of Equity Average data on file, last reported at $197.5 million in Q2 2025.

• Equity Average for Q2 2025 came in at $197.5 million, changed N/A year-over-year; the trailing twelve-month figure through Jun 2025 was $197.5 million (changed N/A YoY), and the FY2025 annual result was $216.1 million, down 2.62% from the prior year.
• Equity Average fell to $197.5 million in Q2 2025 per NBP's latest filing, from $199.8 million in the prior quarter.
• Over five years, Equity Average peaked at $847.3 million in Q2 2021 and troughed at $197.5 million in Q2 2025.
• A 5-year average of $443.9 million and a median of $373.3 million in 2023 frame the typical range for Equity Average.
• The sharpest annual moves came in 2021 and 2023: Equity Average increased 11.33% in 2021, then plunged 43.13% in 2023.
• A 5-year view of Equity Average shows it stood at $779.4 million in 2021, then plunged by 35.29% to $504.4 million in 2022, then declined by 25.99% to $373.3 million in 2023, then sank by 43.87% to $209.5 million in 2024, then fell by 5.72% to $197.5 million in 2025.
• Business Quant data shows NBP's Equity Average at $197.5 million in Q2 2025, $199.8 million in Q1 2025, and $209.5 million in Q4 2024.